M J Rybak|S C Boike - JoVE Visualize

Showing results (71-80 of 131) with videos related to

Pageof 14

Sort By:

Journal of Clinical Pharmacology|May 23, 1998

Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal menD E Wilson, A W Meikle, S C Boike, et al.

Pharmacotherapy|January 1, 1994

Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureusD Stanley, B J McGrath, K C Lamp, et al.

Pharmacotherapy|May 16, 2000

Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal functionM M Neuhauser, P S McKinnon, E Hershberger, et al.

British Journal of Clinical Pharmacology|October 9, 1998

Effect of age and gender on the pharmacokinetics of eprosartanD M Tenero, D E Martin, A K Miller, et al.

Journal of Clinical Pharmacology|August 1, 1996

Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of doseD R Brocks, A W Meikle, S C Boike, et al.

Antimicrobial Agents and Chemotherapy|March 1, 1996

Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infectionsJ K James, S M Palmer, D P Levine, et al.

Drug Intelligence & Clinical Pharmacy|November 1, 1987

Increased theophylline concentrations secondary to ciprofloxacinM J Rybak, S K Bowles, P H Chandrasekar, et al.

Pharmacotherapy|August 6, 1998

Omeprazole-induced exfoliative dermatitisJ A Rebuck, M J Rybak, D P Ramos, et al.

Antimicrobial Agents and Chemotherapy|January 30, 1999

Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureusJ R Aeschlimann, L D Dresser, G W Kaatz, et al.

Antimicrobial Agents and Chemotherapy|June 1, 1997

Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection modelM J Rybak, H H Houlihan, R C Mercier, et al.

Pageof 14

Showing results (71-80 of 131) with videos related to

Sort By:

Pageof 14

Journal of Clinical Pharmacology|May 23, 1998

Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal menD E Wilson, A W Meikle, S C Boike, et al.

Pharmacotherapy|January 1, 1994

Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureusD Stanley, B J McGrath, K C Lamp, et al.

Pharmacotherapy|May 16, 2000

Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal functionM M Neuhauser, P S McKinnon, E Hershberger, et al.

British Journal of Clinical Pharmacology|October 9, 1998

Effect of age and gender on the pharmacokinetics of eprosartanD M Tenero, D E Martin, A K Miller, et al.

Journal of Clinical Pharmacology|August 1, 1996

Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of doseD R Brocks, A W Meikle, S C Boike, et al.

Antimicrobial Agents and Chemotherapy|March 1, 1996

Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infectionsJ K James, S M Palmer, D P Levine, et al.

Drug Intelligence & Clinical Pharmacy|November 1, 1987

Increased theophylline concentrations secondary to ciprofloxacinM J Rybak, S K Bowles, P H Chandrasekar, et al.

Pharmacotherapy|August 6, 1998

Omeprazole-induced exfoliative dermatitisJ A Rebuck, M J Rybak, D P Ramos, et al.

Antimicrobial Agents and Chemotherapy|January 30, 1999

Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureusJ R Aeschlimann, L D Dresser, G W Kaatz, et al.

Antimicrobial Agents and Chemotherapy|June 1, 1997

Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection modelM J Rybak, H H Houlihan, R C Mercier, et al.

Pageof 14